Factor 5 and Factor 2 heterozygous positivity and complications in living donor liver transplant donors.
Factor 2
Factor 5
heterozygous
liver
mutation
transplant
Journal
Northern clinics of Istanbul
ISSN: 2536-4553
Titre abrégé: North Clin Istanb
Pays: Turkey
ID NLM: 101684520
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
06
2023
revised:
16
08
2023
accepted:
30
08
2023
medline:
13
10
2023
pubmed:
13
10
2023
entrez:
13
10
2023
Statut:
epublish
Résumé
Factor 2 and Factor 5 mutations are among the most common procoagulant genetic disorders and are routinely evaluated in donor preparation. Homozygous mutations are contraindicated for surgery, but heterozygous mutations cannot be said to be an impediment. We aimed to investigate the effect of heterozygous gene mutation of F2 and/or F5 on complications. In our study, 210 living liver donors were examined. The available data of Factor 2 and 5 heterozygous positive donors were evaluated in terms of 21 donor patients and 30 liver recipients. The heterozygous positive group and the control group were statistically compared in terms of age, gender, length of hospital stay, post-operative deep vein thrombosis, pulmonary embolism, portal vein thrombosis, bile duct stenosis and bile leakage complications, lung infection and atelectasis, and wound infection. In addition, these patients were statistically compared in terms of laboratory tests. In addition, complications in recipients implanted with mutant grafts were evaluated statistically and numerically. Hospital staying was longer statistically in the donor group with heterozygous mutations than in the control group. Hemoglobin and albumin blood levels were lower (p=0.031, p=0.016); INR and ALT levels were higher (p=0.005, p=0.047) statistically in the control group than in the donor group with heterozygous mutations. There was no statistically significant difference between heterozygous mutant groups in terms of biliary tract complications and hepatic vessel thrombosis in recipients. Considering the longer hospital stay in the presence of these mutations, the increased need for treatment in this process and the close follow-up of liver functions should be considered.
Identifiants
pubmed: 37829741
doi: 10.14744/nci.2023.49354
pii: NCI-10-550
pmc: PMC10565751
doi:
Types de publication
Journal Article
Langues
eng
Pagination
550-555Informations de copyright
© Copyright 2023 by Istanbul Provincial Directorate of Health.
Déclaration de conflit d'intérêts
No conflict of interest was declared by the authors.
Références
Curr Opin Nephrol Hypertens. 2001 May;10(3):409-14
pubmed: 11342806
Clin Transplant. 2006 Jan-Feb;20(1):132-5
pubmed: 16556168
Thromb Haemost. 1997 Dec;78(6):1527-8
pubmed: 9423807
Transplant Rev (Orlando). 2016 Oct;30(4):247-52
pubmed: 27531698
Lancet. 1995 Oct 28;346(8983):1133-4
pubmed: 7475606
Thromb Haemost. 1997 Jul;78(1):631-5
pubmed: 9198229
Thromb Haemost. 1998 Apr;79(4):706-8
pubmed: 9569177
Hippokratia. 2015 Oct-Dec;19(4):309-13
pubmed: 27688694
Crit Care Med. 2004 May;32(5 Suppl):S313-9
pubmed: 15118537
Thromb Res. 2019 Oct;182:75-78
pubmed: 31472339
Crit Care Med. 2004 May;32(5 Suppl):S239-46
pubmed: 15118525
J Thromb Haemost. 2008 Aug;6(8):1336-43
pubmed: 18485088
Case Rep Gastrointest Med. 2015;2015:816914
pubmed: 26640725
Pediatr Transplant. 2006 Feb;10(1):114-8
pubmed: 16499600
Ann Intern Med. 1998 Jul 15;129(2):89-93
pubmed: 9669991
JSLS. 2012 Jan-Mar;16(1):166-8
pubmed: 22906349
World J Gastroenterol. 2011 Dec 7;17(45):5007-13
pubmed: 22174551
Liver Transpl Surg. 1998 Jan;4(1):58-61
pubmed: 9457968
S Afr J Surg. 2019 Sep;57(3):11-16
pubmed: 31392859
Clin Res Hepatol Gastroenterol. 2011 Sep;35(8-9):526-33
pubmed: 21570930